Trial Profile
An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Effect of Lansoprazole on the Pharmacokinetics of Neratinib in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2016
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Lansoprazole
- Indications Breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Puma Biotechnology
- 15 Sep 2016 Results assessing pharmacokinetics published in the British Journal of Clinical Pharmacology.
- 12 Jan 2015 New trial record